Compass Pathways gains Stifel's Buy rating as its COMP360 psilocybin treatment advances in Phase 3 trials. Key depression study data expected in 2025-2026.

Intra-Cellular reports mixed fourth-quarter 2024 results, wherein earnings miss estimates but revenues beat the same driven ...

Escalating concerns over impending tariffs and President Trump's foreign policies have fueled uncertainty and instability in ...

The diagnosis of major depressive disorder is based on the patient's self-reported experiences, behavior reported by relatives or friends, and a mental status examination. There is no laboratory ...

While the bulk (pun intended) of news coverage these days is focused on GLP-1 drugs like Ozempic that cause weight loss, licensed pharmacist Dr. Kati Forbes told The Post four medications are ...